ATLAS : A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy

Alberto Bossi,David P. Dearnaley,Michael R. McKenzie,E. Baskin-Bey,Robert C. Tyler,Bertrand Tombal,Stephen J. Freedland,Roach, M. , I I I,Anders Widmark,Adam P. Dicker,Thomas Wiegel,Neal D. Shore,M. R. Smith,Menggang Yu,Thian Kheoh,Shibu Thomas,Howard M. Sandler

ATLAS : A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy

2016

Alberto Bossi
David P. Dearnaley
Michael R. McKenzie
E. Baskin-Bey
Robert C. Tyler
Bertrand Tombal
Stephen J. Freedland
Roach, M. , I I I
Anders Widmark
Adam P. Dicker
Thomas Wiegel
Neal D. Shore
M. R. Smith
Menggang Yu
Thian Kheoh
Shibu Thomas
Howard M. Sandler

ATLAS : A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy

Keywords:

Radiology
General surgery
Apalutamide
Medical physics
Prostate cancer
Medicine
Radiation therapy
Atlas (anatomy)
in patient
Oncology
locally advanced
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations